Homeβ€ΊStocksβ€ΊANTHEM: Anthem Biosciences Ltd

Anthem Biosciences Ltd

NSEBSEANTHEMHealthcareConcall transcript
β‚Ή862.30
β–Ό -β‚Ή10.25 Β (-1.17%)
NSE Β· Last Β· 11 Oct, 06:00 pm
Price
daily

Overlay is FY EPS implied P/E (stepped), not TTM.

Quant & risk snapshot

Metrics calculated as of last available close.

1W
β€”
1M
β€”
3M
β€”
6M
β€”
1Y
β€”
P/E now
β€”
3Y CAGR
β€”
5Y CAGR
β€”
1Y vol
β€”
5Y max DD
β€”
5Y EPS CAGR
β€”
5Y rerating
β€”
55
Empire Scoreβ„’
Fair
6
Piotroski
6/9 F-Score
22.3%
ROE
Return on equity
30.4%
ROCE
Return on capital
GRAHAM VALUE
β‚Ή112.67
~665% Premium
The Numbers That Matter
End-of-day filing snapshot Β· β€” when not disclosed
β€”EV / EBITDA
Financial Health Story
Revenue
Net Profit
Data is compiled from end-of-day institutional filings for educational structural analysis. Compare with audited filings before making financial decisions. Missing bars or β€” values are normal for banks or thin coverage. Chart magnitudes are shown in β‚Ή Cr (Indian grouping).
SWOT Analysis
AI Powered

Unlock strengths, weaknesses, opportunities, and threats in clear, simple English.

Peter Lynch valuation bands

Bands from median Β±1Οƒ of FY-implied P/E over the plotted window. These are not TTM percentile bands.

Base-100 compounding

Price, revenue, and net profit rebased to 100 at the first month where all series are positive. Annual fundamentals are step-held to month-end.

Peer Comparison

Sector: HealthcareΒ· 50 sector peers

Scroll horizontally to compare all sector peers.

MetricsANTHEMYouAPOLLOHOSPApollo Hospitals Enterprise LtdCIPLACipla LtdDIVISLABDivis Laboratories LtdDRREDDYDr Reddys Laboratories LtdSUNPHARMASun Pharmaceutical Industries LtdABBOTINDIAAbbott India LtdAJANTPHARMAjanta Pharma LtdALKEMAlkem Laboratories LtdASTERDMAster DM Quality Care LtdAUROPHARMAAurobindo Pharma LtdBIOCONBiocon LtdBLUEJETBlue Jet Healthcare LtdCAPLIPOINTCaplin Point Laboratories LtdCOHANCECohance Lifesciences LtdCONCORDBIOConcord Biotech LtdEMCUREEmcure Pharmaceuticals LtdERISERIS Lifesciences LtdFORTISFortis Healthcare LtdGLANDGland Pharma LtdGLAXOGlaxosmithkline Pharmaceuticals LtdGLENMARKGlenmark Pharmaceuticals LtdGRANULESGranules India LtdIKSInventurus Knowledge Solutions LtdINDGNIndegene LtdIPCALABIpca Laboratories LtdJBCHEPHARMJ B Chemicals & Pharmaceuticals LtdJUBLPHARMAJubilant Pharmova LtdKIMSKrishna Institute of Medical Sciences LtdLALPATHLABDr Lal Pathlabs LtdLAURUSLABSLaurus Labs LtdLENSKARTLenskart Solutions LtdLUPINLupin LtdMANKINDMankind Pharma LtdMAXHEALTHMax Healthcare Institute LtdMEDANTAGlobal Health LtdNATCOPHARMNatco Pharma LtdNEULANDLABNeuland Laboratories LtdNHNarayana Hrudayalaya LtdONESOURCEOneSource Specialty Pharma LtdPFIZERPfizer LtdPOLYMEDPoly Medicure LtdPPLPHARMAPiramal Pharma LtdRAINBOWRainbow Childrens Medicare LtdSAGILITYSagility LtdSAILIFESai Life Sciences LtdSYNGENESyngene International LtdTORNTPHARMTorrent Pharmaceuticals LtdVIJAYAVijaya Diagnostic Centre LtdWOCKPHARMAWockhardt LtdZYDUSLIFEZydus Lifesciences Ltd
Current Priceβ‚Ή862.3β‚Ή8,089.5β‚Ή1,379.3β‚Ή6,533β‚Ή1,274β‚Ή1,747.3β‚Ή26,295β‚Ή2,912.2β‚Ή5,239β‚Ή726.95β‚Ή1,429.2β‚Ή416.8β‚Ή452.5β‚Ή1,988.1β‚Ή428.9β‚Ή1,166.2β‚Ή1,704.4β‚Ή1,362.1β‚Ή929.4β‚Ή2,277β‚Ή2,188.8β‚Ή2,184.6β‚Ή777.55β‚Ή1,670.2β‚Ή518.45β‚Ή1,507.7β‚Ή2,129.6β‚Ή991.75β‚Ή784.45β‚Ή1,617.2β‚Ή1,381.7β‚Ή521β‚Ή2,249.8β‚Ή2,420.4β‚Ή993.45β‚Ή1,105.55β‚Ή1,092β‚Ή14,449β‚Ή1,770.5β‚Ή1,784.8β‚Ή4,764β‚Ή1,321.4β‚Ή166.29β‚Ή1,241.9β‚Ή41.74β‚Ή1,047.95β‚Ή440.25β‚Ή4,182.9β‚Ή1,513.6β‚Ή2,265.6β‚Ή1,203.9
P/E Ratio87.4Γ—59.8Γ—30.7Γ—82.9Γ—30.0Γ—35.3Γ—0.0Γ—38.8Γ—27.4Γ—183.0Γ—25.4Γ—84.4Γ—77.1Γ—29.9Γ—156.0Γ—55.1Γ—34.9Γ—27.5Γ—62.8Γ—41.6Γ—45.7Γ—21.7Γ—32.7Γ—39.1Γ—33.5Γ—36.1Γ—53.8Γ—41.8Γ—155.0Γ—57.5Γ—96.3Γ—182.0Γ—16.0Γ—44.4Γ—67.2Γ—66.9Γ—12.8Γ—58.8Γ—44.5Γ—0.0Γ—120.0Γ—54.9Γ—0.0Γ—52.6Γ—20.5Γ—89.5Γ—51.7Γ—82.2Γ—83.2Γ—92.3Γ—24.7Γ—
P/B Ratio16.0Γ—13.1Γ—3.3Γ—10.3Γ—2.6Γ—5.3Γ—0.0Γ—9.5Γ—4.6Γ—14.4Γ—2.4Γ—2.0Γ—0.0Γ—5.1Γ—4.5Γ—8.0Γ—6.8Γ—4.6Γ—6.8Γ—4.4Γ—19.4Γ—5.9Γ—4.3Γ—10.6Γ—4.3Γ—5.7Γ—8.2Γ—1.9Γ—8.9Γ—12.1Γ—17.4Γ—12.2Γ—4.3Γ—5.9Γ—9.0Γ—9.4Γ—1.7Γ—14.8Γ—7.8Γ—3.0Γ—0.0Γ—5.7Γ—3.5Γ—8.7Γ—2.0Γ—12.0Γ—3.4Γ—15.6Γ—16.3Γ—7.4Γ—4.5Γ—
ROE (%)22.3%21.2%11.6%16.5%11.2%16.0%34.7%27.1%18.9%11.3%10.1%1.4%52.1%20.9%4.9%12.5%20.1%18.7%11.2%10.7%45.6%23.6%13.8%31.4%14.4%15.7%18.9%6.5%11.3%22.3%18.3%6.3%28.7%13.1%14.7%15.2%17.1%21.2%20.5%-1.1%19.8%9.0%-3.8%15.9%10.6%15.4%7.8%27.4%18.3%6.1%21.2%
ROCE (%)30.4%17.4%15.5%22.0%13.0%20.5%46.7%34.5%21.2%11.6%12.9%3.6%57.3%24.2%5.8%17.1%24.0%14.1%13.4%15.1%61.4%39.8%15.5%31.5%18.8%17.0%25.4%9.0%9.5%28.0%17.8%8.1%29.9%13.5%14.7%17.4%17.4%26.5%15.5%57.0%27.2%12.5%2.5%17.4%13.4%19.6%10.0%15.2%20.5%7.5%21.1%
EV / EBITDAβ€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”
Dividend Yield (%)22.00%23.00%95.00%33.00%70.00%86.00%1.96%91.00%1.01%40.00%24.00%13.00%21.00%31.00%0.00%52.00%19.00%55.00%11.00%70.00%2.02%21.00%21.00%0.00%39.00%31.00%91.00%50.00%0.00%73.00%10.00%0.00%88.00%4.00%20.00%4.00%61.00%15.00%24.00%0.00%1.86%21.00%7.00%24.00%33.00%0.00%33.00%79.00%13.00%0.00%8.00%

Peer figures are drawn from the same educational filing snapshot as the main report. Missing values show β€”. EV/EBITDA and yields are often unavailable for banks. Compare filings before investing.

Corporate filings

Annual reports, investor decks, and concall links. URLs only. We do not host PDFs.

Annual reports

Newest period first.

Annual Report 2025 from web
Annual Report 2025 from web
Open
Financial Year 2025 from web
Financial Year 2025 from webLatest
Open
DRHP
DRHP
Open

Investor presentations

Newest period first.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 22 Jul - Audio recording of Q1 FY2027 earnings call held July 22, 2026, posted on website.
Announcement under Regulation 30 (LODR)-AnalystLatest
Open
Investor presentation β€” May 2026
May 2026
Open
Investor presentation β€” Feb 2026
Feb 2026
Open
Investor presentation β€” Jul 2026
Jul 2026
Open
Announcement Under Regulation 30 Of LODR-Update In The Outcome Of The Board Meeting Held On April 22, 2026 22 Apr - Board approved S.R. Batliboi as auditor and sought approval for β‚Ή1,276.83 million promoter payout from investor divestment.
Announcement Under Regulation 30 Of LODR
Open
Investor presentation β€” Nov 2025
Nov 2025
Open
Investor presentation β€” Aug 2025
Aug 2025
Open

Concall transcripts

Newest period first.

Concall transcript β€” Jul 2026
Jul 2026Latest
Open
Concall transcript β€” May 2026
May 2026
Open
Concall transcript β€” Feb 2026
Feb 2026
Open
Concall transcript β€” Aug 2025
Aug 2025
Open
Concall transcript β€” Nov 2025
Nov 2025
Open
Technical Snapshot
Educational only
Technical data shown for educational purposes. Not investment advice.
Financial Health Checklist
5/9 passΒ· 1 data N/A
FAIL
Quarterly revenue growthRevenue trend is weak or declining across recent quarters.
PASS
Net profit trendAll last 4 quarters are profitable.
PASS
ROEROE 22.3% (β‰₯15%).
PASS
ROCEROCE 30.4% (β‰₯12%).
WATCH
Debt / EquityD/E 1.77 (1.0–2.0).
PASS
Net marginNet margin 27.9% (β‰₯10%).
FAIL
P/E ratioP/E 87.4Γ— (β‰₯60).
N/A
EV / EBITDAData unavailable for this sector.
PASS
Dividend yieldYield 22.00% (β‰₯1.5%).

N/A means the metric is not available in the educational dataset (common for banks or thin coverage). Those rows are not scored as fail.

Institutional ratios

Piotroski F-Score, Altman Z, cash conversion cycle, and PEG. Derived from the same filing-based fundamentals as the rest of the report (indicative only, not investment advice).

Piotroski F-Score
6/9
Altman Z-Score
27.41Safe
Cash conversion cycle
β€”
PEG ratio
β€”
Latest News
Tap a headline Β· Quick read
Loading headlines…